Kazia Therapeutics preclinical data: paxalisib plus pembrolizumab reduces MSS/pMMR tumors
Preclinical model results show paxalisib monotherapy significantly reduced tumor burden in MSS/pMMR colorectal cancer, with pembrolizumab adding a further reduction. Paxalisib was well tolerated as monotherapy and with checkpoint inhibition.